drugset / Trial / NCT02563925

Brain Irradiation and Tremelimumab in Metastatic Breast Cancer

NCT02563925

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to see if the combination of tremelimumab and durvalumab with brain radiation therapy can help treat this type of breast cancer that has spread to the brain.

Timeline

Start
2015-09-18
Primary completion
2021-07-14
Completion
2021-07-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Durvalumab Monoclonal antibody 1500 mg
Subject Trastuzumab Monoclonal antibody
Subject Tremelimumab Monoclonal antibody 75 mg

Indications